🎉 M&A multiples are live!
Check it out!

Monte Rosa Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Monte Rosa Therapeutics and similar public comparables like Vivoryon Therapeutics, Galapagos, and Pharming.

Monte Rosa Therapeutics Overview

About Monte Rosa Therapeutics

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.


Founded

2019

HQ

United States of America
Employees

134

Website

monterosatx.com

Financials

LTM Revenue $67.5M

LTM EBITDA -$96.7M

EV

-$58.2M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Monte Rosa Therapeutics Financials

Monte Rosa Therapeutics has a last 12-month revenue of $67.5M and a last 12-month EBITDA of -$96.7M.

In the most recent fiscal year, Monte Rosa Therapeutics achieved revenue of $75.6M and an EBITDA of -$73.0M.

Monte Rosa Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Monte Rosa Therapeutics valuation multiples based on analyst estimates

Monte Rosa Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a $75.6M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$137M -$73.0M XXX XXX XXX
EBITDA Margin -Infinity% -97% XXX XXX XXX
Net Profit -$109M -$135M XXX XXX XXX
Net Margin -Infinity% -179% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Monte Rosa Therapeutics Stock Performance

As of April 15, 2025, Monte Rosa Therapeutics's stock price is $4.

Monte Rosa Therapeutics has current market cap of $271M, and EV of -$58.2M.

See Monte Rosa Therapeutics trading valuation data

Monte Rosa Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$58.2M $271M XXX XXX XXX XXX $-1.10

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Monte Rosa Therapeutics Valuation Multiples

As of April 15, 2025, Monte Rosa Therapeutics has market cap of $271M and EV of -$58.2M.

Monte Rosa Therapeutics's trades at -0.9x LTM EV/Revenue multiple, and 0.6x LTM EBITDA.

Analysts estimate Monte Rosa Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Monte Rosa Therapeutics and 10K+ public comps

Monte Rosa Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$58.2M XXX XXX XXX
EV/Revenue -0.8x XXX XXX XXX
EV/EBITDA 0.8x XXX XXX XXX
P/E -3.7x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -1.5x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Monte Rosa Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Monte Rosa Therapeutics Valuation Multiples

Monte Rosa Therapeutics's NTM/LTM revenue growth is -35%

Monte Rosa Therapeutics's revenue per employee for the last fiscal year averaged $0.6M, while opex per employee averaged $1.2M for the same period.

Over next 12 months, Monte Rosa Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Monte Rosa Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Monte Rosa Therapeutics and other 10K+ public comps

Monte Rosa Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth Infinity% XXX XXX XXX XXX
EBITDA Margin -97% XXX XXX XXX XXX
EBITDA Growth -47% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -132% XXX XXX XXX XXX
Revenue per Employee $0.6M XXX XXX XXX XXX
Opex per Employee $1.2M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 47% XXX XXX XXX XXX
R&D Expenses to Revenue 161% XXX XXX XXX XXX
Opex to Revenue 207% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Monte Rosa Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Small Molecules comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Monte Rosa Therapeutics M&A and Investment Activity

Monte Rosa Therapeutics acquired  XXX companies to date.

Last acquisition by Monte Rosa Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Monte Rosa Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Monte Rosa Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Monte Rosa Therapeutics

When was Monte Rosa Therapeutics founded? Monte Rosa Therapeutics was founded in 2019.
Where is Monte Rosa Therapeutics headquartered? Monte Rosa Therapeutics is headquartered in United States of America.
How many employees does Monte Rosa Therapeutics have? As of today, Monte Rosa Therapeutics has 134 employees.
Who is the CEO of Monte Rosa Therapeutics? Monte Rosa Therapeutics's CEO is Mr. Markus Warmuth.
Is Monte Rosa Therapeutics publicy listed? Yes, Monte Rosa Therapeutics is a public company listed on NAS.
What is the stock symbol of Monte Rosa Therapeutics? Monte Rosa Therapeutics trades under GLUE ticker.
When did Monte Rosa Therapeutics go public? Monte Rosa Therapeutics went public in 2021.
Who are competitors of Monte Rosa Therapeutics? Similar companies to Monte Rosa Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Monte Rosa Therapeutics? Monte Rosa Therapeutics's current market cap is $271M
What is the current revenue of Monte Rosa Therapeutics? Monte Rosa Therapeutics's last 12-month revenue is $67.5M.
What is the current EBITDA of Monte Rosa Therapeutics? Monte Rosa Therapeutics's last 12-month EBITDA is -$96.7M.
What is the current EV/Revenue multiple of Monte Rosa Therapeutics? Current revenue multiple of Monte Rosa Therapeutics is -0.9x.
What is the current EV/EBITDA multiple of Monte Rosa Therapeutics? Current EBITDA multiple of Monte Rosa Therapeutics is 0.6x.
Is Monte Rosa Therapeutics profitable? Yes, Monte Rosa Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.